Patients hospitalized with lower respiratory tract infection: Advantages of sequential treatment;Pacientes hospitalizados con infección del tracto respiratorio inferior: Ventajas del tratamiento secuencial

Medicina Clinica Monografias

Volumn 7, Issue 6, 2006, Pages 30-35

  Calzada, Soledad Reyes ^a   Tomás, Raquel Martínez ^a   Menéndez Villanueva, Rosario ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFDITOREN; CEFIXIME; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CLINICAL EVALUATION; COMORBIDITY; DISEASE EXACERBATION; DRUG COST; DRUG INDICATION; EMPIRIC THERAPY; HOSPITALIZATION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MICROBIOLOGY; MORTALITY; PROGNOSIS; REVIEW; SEQUENTIAL TREATMENT; TREATMENT DURATION;

EID: 34648833322     PISSN: 15771512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-54.
2. Alfageme I, Aspa J, Bello S, et al. Normativas para el diagnóstico y el tratamiento de la neumonía adquirida en la comunidad. Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Arch Bronconeumol. 2005; 41:272-89.
3. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax. 2001;56 Suppl 4:IV1-64.
4. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26:1138-80.
5. Ambrosino N, Armaganidis A, Beurskens H, et al. Chronic obstructive pulmonary disease. European Lung White Book. 2003. p. 34-43.
6. Ambrosino N, Armaganidis A, Beurskens H, et al. Pneumonia. European Lung White Book. 2003;55-65.
7. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998;279:1452-7.
8. Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med. 1999;159:970-80.
9. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336: 243-50.
10. Menéndez R, Torres A, Rodríguez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis. 2004;39: 1783-90.
11. Ramírez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. 1999;159:2449-54.
12. Weingarten SR, Riedinger MS, Hobson P, et al. Evaluation of a pneumonia practice guideline in an interventional trial. Am J Respir Crit Care Med. 1996;153:1110-5.
13. Weingarten SR, Riedinger MS, Varis G, et al. Identification of low-risk hospitalized patients with pneumonia. Implications for early conversion to oral antimicrobial therapy. Chest. 1994;105:1109-15.
14. Fine MJ, Stone RA, Lave JR, et al. Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial. Am J Med. 2003;115:343-51.
15. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest. 1996;110: 965-71.
16. Ramírez JA. Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study. Semin Respir Crit Care Med. 2005; 26:543-52.
17. Rhew DC, Riedinger MS, Sandhu M, Bowers C, Greengold N, Weingarten SR. A prospective, multicenter study of a pneumonia practice guideline. Chest. 1998;114:115-9.
18. Omidvari K, De Boisblanc BP, Karam G, Nelson S, Haponik E, Summer W. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med. 1998;92:1032-9.
19. Cunha BA. Empiric therapy of community-acquired pneumonia: guidelines for the perplexed? Chest. 2004;125:1913-9.
20. Sanders WE Jr, Morris JF, Alessi P, et al. Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with «usual care» in a multicenter clinical trial. Am J Med. 1991;91:261-6.
21. Cunha BA. Intravenous to oral antibiotic switch therapy. Drugs Today (Barc). 2001;37:311-9.
22. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother. 2002;46:1746-54.
23. Katz E, Larsen LS, Fogarty CM, Hamed K, Song J, Choudhri S. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med. 2004;27: 395-405.
24. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997; 41:1965-72.
25. Van der Eerden MM, Vlaspolder F, De Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax. 2005;60:672-8.
26. Nathwani D. Sequential switch therapy for lower respiratory tract infections: a European perspective. Chest. 1998;113:S211-8.
27. Soriano F, Granizo JJ, Fenoll A, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: results from the cefditoren surveillance program. J Chemother. 2003;15:107-12.
28. Álvarez-Sala JL, Kardos P, Martínez-Beltrán J, Coronel P, Aguilar L. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother. 2006;50:1762-7.
29. Fogarty CM, Cyganowski M, Palo WA, Horn RC, Craig WA. A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study. Clin Ther. 2002;24:1854-70.
30. ATS Guidelines for the management of adults with hospital-acquired v-a, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171:388-416.
31. Ramírez JA. Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis. 1995;22:219-23.
32. Ramírez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995;155: 1273-6.
33. Van der Eerden MM, De Graaff CS, Vlaspolder F, Bronsveld W, Jansen HM, Boersma WG. Evaluation of an algorithm for switching from IV to PO therapy in clinical practice in patients with community-acquired pneumonia. Clin Ther. 2004;26:294-303.
34. Castro-Guardiola A, Viejo-Rodríguez AL, Soler-Simón S, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med. 2001;111:367-74.
35. Rhew DC, Tu GS, Ofman J, Henning JM, Richards MS, Weingarten SR. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med. 2001;161:722-7.
36. Hendrickson JR. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother. 1995;29:561-5.
37. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA. 2000;283: 749-55.